Evidence map›Paper›PMID 26100703›Full record

ArticleAntimicrobial agents and chemotherapy2015

Variation in resistance traits, phylogenetic backgrounds, and virulence genotypes among Escherichia coli clinical isolates from adjacent hospital campuses serving distinct patient populations.

Sarah M Drawz, Stephen Porter, Michael A Kuskowski, Brian Johnston, Connie Clabots, Susan Kline, Patricia Ferrieri, James R Johnson

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Rapid Emergence, Subsidence, and Molecular Detection ofJournal of clinical microbiology · 2019
    Article
  5. Phylogenomic Analysis of Extraintestinal PathogenicAntimicrobial agents and chemotherapy · 2019
    Article
  6. Epidemiology and Antimicrobial Resistance Characteristics of the Sequence Type 131-H30 Subclone Among Extraintestinal Escherichia coli Collected From US Children.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018
    Article
  7. The PandemicOpen forum infectious diseases · 2017
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sarah M DrawzUniversity of Minnesota, Minneapolis, Minnesota, USA drawz007@umn.edu.
Stephen PorterVeterans Affairs Medical Center, Minneapolis, Minnesota, USA.
Michael A KuskowskiVeterans Affairs Medical Center, Minneapolis, Minnesota, USA.
Brian JohnstonVeterans Affairs Medical Center, Minneapolis, Minnesota, USA.
Connie ClabotsVeterans Affairs Medical Center, Minneapolis, Minnesota, USA.
Susan KlineUniversity of Minnesota, Minneapolis, Minnesota, USA.
Patricia FerrieriUniversity of Minnesota, Minneapolis, Minnesota, USA.
James R JohnsonUniversity of Minnesota, Minneapolis, Minnesota, USA Veterans Affairs Medical Center, Minneapolis, Minnesota, USA.

Funding

Emergence of E. coli sequence type ST131I01CX000192 · VA · MINNEAPOLIS VA MEDICAL CENTER · PI JOHNSON, JAMES R · 2009 to 2013
–
Gut reservoir of E. coli ST131I01CX000920 · VA · MINNEAPOLIS VA MEDICAL CENTER · PI JOHNSON, JAMES R · 2014 to 2021
–
CSRD VA I01 CX000192CSRD VA I01 CX000920
6 · The paper itself

Abstract

Escherichia coli sequence type 13 (ST131), an emergent cause of multidrug-resistant extraintestinal infections, has important phylogenetic subsets, notably the H30 and H30Rx subclones, with distinctive resistance profiles and, possibly, clinical associations. To clarify the local prevalence of these ST131 subclones and their associations with antimicrobial resistance, ecological source, and virulence traits, we extensively characterized 233 consecutive E. coli clinical isolates (July and August 2013) from the University of Minnesota Medical Center-Fairview Infectious Diseases and Diagnostic Laboratory, Minneapolis, MN, which serves three adjacent facilities (a children's hospital and low- and high-acuity adult facilities). ST131 accounted for 26% of the study isolates (more than any other clonal group), was distributed similarly by facility, and was closely associated with ciprofloxacin resistance and extended-spectrum β-lactamase (ESBL) production. The H30 and H30Rx subclones accounted for most ST131 isolates and for the association of ST131 with fluoroquinolone resistance and ESBL production. Unlike ST131 per se, these subclones were distributed differentially by hospital, being most prevalent at the high-acuity adult facility and were absent from the children's hospital. The virulence gene profiles of ST131 and its subclones were distinctive and more extensive than those of other fluoroquinolone-resistant or ESBL-producing isolates. Within ST131, bla CTX-M-15 was confined to H30Rx isolates and other bla CTX-M variants to non-Rx H30 isolates. Pulsed-field gel electrophoresis documented a predominance of globally distributed pulsotypes and no local outbreak pattern. These findings help clarify the epidemiology, ecology, and bacterial correlates of the H30 and H30Rx ST131 subclones by documenting a high overall prevalence but significant segregation by facility, strong associations with fluoroquinolone resistance and specific ESBL variants, and distinctive virulence gene associations that may confer fitness advantages over other resistant E. coli.

Indexed as

Anti-Bacterial AgentsCiprofloxacinDrug Resistance, Multiple, BacterialElectrophoresis, Gel, Pulsed-FieldEscherichia coliEscherichia coli ProteinsFluoroquinolonesGenotypeHospitalsHumansPhylogenyVirulenceAnti-Bacterial AgentsCiprofloxacinEscherichia coli ProteinsFluoroquinolones

Identifiers

PMID26100703
PMCPMC4538515

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.